Back |
home / stock / avir / avir message board
Subject | By | Source | When |
---|---|---|---|
$AVIR up 30% @ 45.00 > As Barron's | crudeoil24 | investorshub | 10/01/2021 11:31:16 AM |
The stock is overvalued, IMO. | DewDiligence | investorshub | 09/20/2021 9:55:07 PM |
What is this chart going to do? It's | rtrstock | investorshub | 09/20/2021 9:48:14 PM |
Josh Nathan-Kazis | Paullee | investorshub | 09/09/2021 5:00:22 PM |
good news today | Paullee | investorshub | 06/30/2021 4:01:23 PM |
$AVIR 2 trials estimated to end within a | tulla236a | investorshub | 05/27/2021 2:27:46 PM |
https://twitter.com/LanahanJonathan/status/1390641837132632069 | tulla236a | investorshub | 05/07/2021 12:27:05 PM |
i averaged down but still need $25 to | tulla236a | investorshub | 05/07/2021 12:20:19 PM |
I think i caught it this time, AVIR | Mikey | investorshub | 05/06/2021 7:43:45 PM |
trying again........21.31 | Mikey | investorshub | 05/06/2021 6:04:44 PM |
phase 3 started!!!!! | tulla236a | investorshub | 04/29/2021 12:21:06 PM |
I gave it a whirl......no go........too early....$500 hit | Mikey | investorshub | 04/28/2021 3:25:03 PM |
it's like a toy airplane with rubber band | tulla236a | investorshub | 04/28/2021 3:23:34 PM |
severely oversold........pay attention! | Mikey | investorshub | 04/28/2021 2:59:35 PM |
LOOKS GOOD IF IT $CAN MOVE FAR AWAY | otcmoneydoubler | investorshub | 10/30/2020 5:01:10 PM |
News, Short Squeeze, Breakout and More Instantly...
Atea Pharmaceuticals Inc. Company Name:
AVIR Stock Symbol:
NASDAQ Market:
Atea Pharmaceuticals Inc. Website:
97% SVR12 Rate Observed with 8 Weeks of Treatment in Lead-In Cohort of HCV-Infected Patients in Ongoing Phase 2 Clinical Study EASL Presentations Continue to Support Best-in-Class Potential with High Antiviral Potency, Short Treatment Duration, Low Risk of Drug Interaction and High Barr...
Presentations to Include New Antiviral Efficacy Results, Including SVR12 Data, from Lead-In Cohort of Ongoing Phase 2 HCV Trial Data Also Highlight the High Prevalence of Pre-Existing NS5A Resistance-Associated Substitutions (RAS) Detected in HCV-infected Patients BOSTON, May 22, 20...
Full Enrollment Achieved in Global Phase 3 SUNRISE-3 Trial for Treatment of COVID-19 with Results Expected 2H’24 Global Phase 2 HCV Study On Track to Report Complete SVR12 Results 2H’24 Multiple Presentations Showcasing Preclinical and New Phase 2 Efficacy Data to ...